Fusion Antibodies PLC Notice of Results (0310F)
12 Novembre 2020 - 8:00AM
UK Regulatory
TIDMFAB
RNS Number : 0310F
Fusion Antibodies PLC
12 November 2020
Fusion Antibodies plc
("Fusion" or the "Company")
Notice of Results
Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical
antibody discovery, engineering and supply for both therapeutic
drug and diagnostic applications, announces it will release its
unaudited interim results for the six months ended 30 September
2020 on Friday, 20 November 2020.
Fusion will host an online live presentation open to all
investors on Monday, 23 November at 3.00pm, delivered by Paul Kerr,
CEO and James Fair, CFO. The Company is committed to providing an
opportunity for all existing and potential investors to hear
directly from management on its results whilst additionally
providing an update on the business and current trading.
The presentation will be hosted through the digital platform
Investor Meet Company.
Investors can sign up to Investor Meet Company for free and add
to meet Fusion Antibodies plc via the following link:
https://www.investormeetcompany.com/fusion-antibodies-plc/register-investor
For those investors who have already registered and added to
meet the Company, they will automatically be invited. Questions can
be submitted pre-event via your IMC dashboard or in real time
during the presentation, via the "Ask a Question" function. Whilst
the Company may not be in a position to answer every question it
receives, it will address the most prominent within the confines of
information already disclosed to the market through regulatory
notifications. A recording of the presentation, a PDF of the slides
used, and responses to the Q&A session will be available on the
Investor Meet Company platform afterwards.
Enquiries:
Fusion Antibodies plc www.fusionantibodies.com
Dr Paul Kerr, Chief Executive Officer Via Walbrook PR
James Fair, Chief Financial Officer
Allenby Capital Limited Tel: +44 (0)20 3328 5656
James Reeve / Asha Chotai (Corporate
Finance)
Tony Quirke (Sales)
Walbrook PR Tel: +44 (0)20 7933 8780 or fusion@walbrookpr.com
Anna Dunphy Mob: +44 (0)7876 741 001
Paul McManus Mob: +44 (0)7980 541 893
About Fusion Antibodies plc
Fusion is a Belfast based contract research organisation ("CRO")
providing a range of antibody engineering services for the
development of antibodies for both therapeutic drug and diagnostic
applications.
The Company's ordinary shares were admitted to trading on AIM on
18 December 2017. Fusion provides a broad range of services in
antibody generation, development, production, characterisation and
optimisation. These services include antigen expression, antibody
production, purification and sequencing, antibody humanisation
using Fusion's proprietary CDRx(TM) platform and the production of
antibody generating stable cell lines to provide material for use
in clinical trials. Since 2012, the Company has successfully
sequenced and expressed over 250 antibodies and successfully
completed over 200 humanisation projects and has an international,
blue-chip client base, which has included eight of the top 10
global pharmaceutical companies by revenue.
The Company was established in 2001 as a spin out from Queen's
University Belfast. The Company's mission is to enable
pharmaceutical and diagnostic companies to develop innovative
products in a timely and cost-effective manner for the benefit of
the global healthcare industry. Fusion Antibodies provides a broad
range of services in antibody generation, development, production,
characterisation and optimisation.
Fusion Antibodies growth strategy is based on combining the
latest technological advances with cutting edge science to deliver
new platforms that will enable Pharma and Biotech companies get to
the clinic faster, with the optimal drug candidate and ultimately
speed up the drug development process.
The global monoclonal antibody therapeutics market was valued at
$135.4 billion in 2018 and is forecast to surpass $212.6 billion in
2022, an increase at a CAGR of 12.0 per cent. for the period 2018
to 2022. In 2017, seven of the world's ten top selling drugs were
antibody-based therapeutics with the combined annual sales of these
drugs exceeding $63.2 billion.
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
RNS may use your IP address to confirm compliance with the terms
and conditions, to analyse how you engage with the information
contained in this communication, and to share such analysis on an
anonymised basis with others as part of our commercial services.
For further information about how RNS and the London Stock Exchange
use the personal data you provide us, please see our Privacy
Policy.
END
NORFLFEELDLLLII
(END) Dow Jones Newswires
November 12, 2020 02:00 ET (07:00 GMT)
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Mar 2024 a Apr 2024
Grafico Azioni Fusion Antibodies (LSE:FAB)
Storico
Da Apr 2023 a Apr 2024